Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
1 month, 1 week ago

Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products. Lilly said Thursday it will expand a Kenosha County, Wisconsin, factory it bought early this year, and the investment will help meet growing demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound. Eli Lilly and Co. said Thursday that it has slated more than $23 billion to construct, expand or acquire manufacturing sites worldwide since 2020.

Eli Lilly Lilly  factory  free  emails  drugs  lilly  zepbound  eli  invests  sign  breaking  expansion  manufacturing  mounjaro  billion  expand  meet  wisconsin  help

History of this topic

Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter
5 months, 1 week ago

Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter

Associated Press  

INDIANAPOLIS — Eli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker. Lilly also hiked its forecast for the year well beyond Wall Street expectations as newer drugs like Zepbound built momentum. Leerink Partners analyst David Risinger noted that insurance coverage of Zepbound …

Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro
7 months, 3 weeks ago

Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro

Associated Press  

Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. The company broke ground for its Lebanon, Indiana, manufacturing plant last year and expects to start making products there near the end of 2026. But Lilly has struggled to make enough …

Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
8 months, 2 weeks ago

Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues

Associated Press  

Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. CEO David Ricks told analysts Tuesday …

Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024
11 months, 1 week ago

Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024

Associated Press  

Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year. Lilly said on Tuesday that revenue could climb as much as 22% this year, as star sellers like the diabetes drug Mounjaro and its new weight-loss counterpart, Zepbound, gain market share. Zepbound, a …

Discover Related